TL;DR: Adults who stayed in JumpstartMD's physician-supervised, low-carbohydrate program lost an average of 11.5 kg — 12.0% of body weight — at 12 months in an analysis of 22,407 patients published in the Journal of Obesity, but fewer than four in ten women and about three in ten men were still enrolled that long, and the study had no control group.
The peer-reviewed paper appeared online on 21 January 2020 and drew on a decade of clinic records. JumpstartMD's current results page reports newer figures from records spanning September 2018 to August 2026: among 4,027 patients who had a usable 12-month measurement, the average loss was 13.2%, or about 27 lb. Those figures are retrospective and company-reported, not peer-reviewed, and the page notes that people who returned for later measurements may not represent those who did not.
The commercial context
Roughly 70% of US adults are overweight or obese, 42% report trying to lose weight, and Americans spend $2.5 billion a year on commercial weight-loss programs, the authors note. They also cite evidence that such programs can produce at least three times the loss achieved by self-directed dieting.
What the study measured
Bourke, Morton and Williams analyzed clinic-recorded weights for 18,769 women and 3,638 men who paid their own way into the San Francisco Bay Area program between 2007 and 2017. There was no comparison group and no randomization. Results were calculated for completers measured at each checkpoint and, separately, with last observation carried forward (LOCF), which keeps a dropout's final weight in the analysis.
The headline numbers
At three months, the 14,999 completers had lost a mean 8.7 kg, or 9.5% of body weight, and 44.5% had crossed the 10% threshold. The six-month figures were 11.8 kg, 12.6% and 66.4% among 11,805 completers; at 12 months, 11.5 kg, 12.0% and 57.6% among 8,514. Counting dropouts at their last recorded weight instead pulled the 12-month result down to 7.7 kg, or 8.4%, with 34.6% reaching 10%.
The gap between those two sets of figures is attrition at work. Completer averages describe people still being weighed; the LOCF estimates assume, in effect, that those who left stopped losing. The paper notes that a 5–10% reduction produces clinically significant health benefits, and both 12-month group averages sit above the 5% mark.
Attendance was the strongest signal
Patients who attended at least 75% of their weekly appointments lost far more than the group overall. Women in that bracket averaged 8.8 kg at three months, 13.1 kg at six and 16.5 kg at 12; men averaged 11.9 kg, 16.5 kg and 19.4 kg. The company's January 2020 announcement described a doubling: patients attending three-quarters or more of weekly visits lost twice as much at six months as those attending half or fewer. Attendance was not randomized, so the pattern is an association in a self-selected group, not proof that extra visits produced the extra loss.
What participants actually did
The program was pay-as-you-go, built around weekly one-on-one visits with health coaches or clinicians and a licensed practitioner on site at each center. Patients ate real, unpackaged food; prepackaged meals and meal replacements were not part of the plan. The paper describes a daily energy deficit of 500 to 1,000 calories and carbohydrate generally held below 50 grams a day, with targets adjusted for starting weight and baseline laboratory results. Body-composition testing and lab work shaped each plan, according to the company's announcement.
Medication nudged weight, but mostly kept people enrolled
Phentermine and phendimetrazine were optional. Their effect on weight appeared only in women and faded quickly: 6.1% more loss than untreated patients at one month, 4.1% at two months and 1.2% at three. The more durable difference was in persistence. At the 12-month analysis, treated women had stayed enrolled 2.7 months longer than untreated women, and treated men 2.4 months longer than untreated men.
How the results compare
The authors concluded that the program produced generally larger losses than published outcomes for commercial programs built on whole foods or packaged meals, and results a little better than, or similar to, meal-replacement diets, according to the Journal of Obesity paper. That is a comparison across studies with different populations and timepoints, not a head-to-head trial, and the authors acknowledge that older published reports may not reflect current practice.
Independent reviewers apply a stricter filter. A 2021 update in Current Obesity Reports, led by Marci Laudenslager, examined randomized trial evidence and identified the National Diabetes Prevention Program, WW, Jenny Craig, Medifast and OPTIFAST as having demonstrated 12-month weight-loss efficacy and safety. The review notes that guidelines support referral to commercial programs with peer-reviewed evidence, while clinicians should weigh the evidence, patient preference and cost.
The limitations that matter most
- No control group, so the diet, coaching, medication and the motivation of people who chose a pay-as-you-go clinic cannot be separated.
- Dietary intake was not statistically verified.
- Income, health literacy and individual medical history were not accounted for.
- Retention was 39.2% among women and 31.8% among men at one year, so the 12-month completer figures rest on a minority of enrollees.
- Sean Bourke, the lead author, was JumpstartMD's chief medical officer; Paul Williams was commissioned to run the statistical analysis and help prepare the manuscript; John Magaña Morton reported no financial interest.
Where the program stands now
JumpstartMD's outcomes page describes 14,119 members and 252,687 clinic-recorded weight measurements from September 2018 through August 2026, with an average 12-month loss of 13.2% among patients who had a qualifying measurement. It also reports that 79.5% of 2,062 patients with a two-year measurement were at least 5% below their starting weight — a figure the page says does not prove steady maintenance — and that 82% of measured weight loss was body fat among 6,765 members with paired InBody scans. The company now advertises GLP-1 prescriptions including Wegovy, Zepbound, Ozempic and Mounjaro at 14 California locations or online, a different drug menu from the 2020 paper's phentermine and phendimetrazine options.
What to take from it
A single-arm program can show that people who stay lose weight; it cannot show why. Ask for a one-year retention rate next to any average loss — the gap between 12.0% and 8.4% in this paper is what attrition does to a headline. Check who wrote and funded the research and whether a comparison group existed. And keep the study's own yardstick in view: 5–10% loss is where health benefits become clinically significant, a range the average completer here exceeded.
